Anzeige
Meldung des Tages: Gold dreht wieder auf: Goldpreis-Comeback – und diese Bohrung liefert 307 Meter „Gold-System“

Indivior Pharmaceuticals Aktie News

Aktie
WKN:  A42086 ISIN:  US45579U1097 US-Symbol:  INDV
35,14 $
+0,14 $
+0,40%
29,769 € 16:16:56 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Dividende
0,42 €
Dividendenrendite
-   %
Index-Zuordnung
-

Indivior Pharmaceuticals News

02.06.25 - PR Newswire
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained PR Newswire
27.05.25 - PR Newswire
Indivior Announces Patrick Barry as Chief Commercial Officer
Indivior Announces Patrick Barry as Chief Commercial Officer PR Newswire
13.05.25 - PR Newswire
Indivior to Participate in Upcoming Investor Events
Indivior to Participate in Upcoming Investor Events PR Newswire
01.05.25 - PR Newswire
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy PR Newswire
24.04.25 - PR Newswire
Indivior Announces Q1 2025 Financial Results
Indivior Announces Q1 2025 Financial Results PR Newswire
04.03.25 - PR Newswire
Indivior Announces Further Changes to Board of Directors
Indivior Announces Further Changes to Board of Directors PR Newswire
27.02.25 - PR Newswire
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer PR Newswire
24.02.25 - PR Newswire
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-​release) Injection PR Newswire
20.02.25 - PR Newswire
Indivior Announces FY and Q4 2024 Financial Results
Indivior Announces FY and Q4 2024 Financial Results PR Newswire
12.02.25 - PR Newswire
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes PR Newswire

Newssuche

Videos

newspaper
02.02.26 -34,11%
Technical Trading Silber Crash!
Silber Short Typ: Turbo Open End WKN: VJ4GQU Hebel: 3,77 Laufzeit: OpenEnd Einstieg: Market ... Mehr »